Home > Rheumatology > ACR 2019 > Vasculitis – Novel Treatment Modalities > Prolonged remission after stop of tocilizumab for patients with giant cell arteritis

Prolonged remission after stop of tocilizumab for patients with giant cell arteritis

Presented By
Prof. John H. Stone, Harvard Medical School, Boston, USA
Conference
ACR 2019
Trial
Phase 3, GiACTA
Treatment with tocilizumab not only led to a reduction in cumulative steroid intake in giant cell arteritis (GCA), but many patients profited from ongoing remission after drug discontinuation [1]. In terms of sustained glucocorticoid-free remission in patients with GCA, therapy with weekly or biweekly tocilizumab 162 mg plus 26-week prednisone tapering demonstrated to be superior to placebo plus 26-week or 52-week prednisone tapering, in the first part of the GiACTA trial [2]. Of included patients from part 1 of GiACTA, 215 entered an open-label second part of the phase 3 trial in order to investigate continued 2-year safety as well as maintenance of efficacy after the stop of treatment with tocilizumab [1]. Data on the amount of steroid use was also analysed. Status of clinical remission was defined by the absence of flare, without requirement of normalisation of C-reactive protein <1 mg/dL. Blinded injections were terminated at week 52 of part ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on